CareDx, Inc. (CDNA) stock
CDNANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 12/3036% above fair value
$79.81−1.36 (-1.68%)
Close on Nov 12, 2026Market cap $4.19BP/E 33.4Yield –
Earnings
CareDx's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 23, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$139.00M
+38.9% on a year earlier
Non-GAAP diluted net income per share, Q3 FY2026
$0.70
$0.28 a year earlier
Latest guidance
Raised
Oct 29, 2026 · 2 items
Quarterly results
Revenue and earnings per share from each of CareDx's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 23, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 29, 2026after the close | $139.00M | +38.9% | $0.35 | $0.70 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 30, 2026after the close | $132.00M | +52.2% | $2.07 | $0.37 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 16, 2026before the open | $118.00M | +39.3% | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 24, 2026after the close | $108.00M | +24.7% | -$0.08 | $0.12 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025after the close | $100.10M | +20.7% | $0.03 | $0.28 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025after the close | $86.70M | -6.1% | -$0.16 | $0.10 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 30, 2025after the close | $84.70M | +17.6% | -$0.19 | $0.09 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 26, 2025after the close | $86.60M | +32.0% | $1.51 | $0.18 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 4, 2024after the close | $82.90M | +23.4% | -$0.14 | $0.14 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 31, 2024after the close | $92.30M | +31.3% | -$0.03 | $0.25 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024after the close | $72.00M | -6.9% | -$0.32 | -$0.03 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024after the close | $65.60M | -20.4% | -$2.21 | -$0.17 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 8, 2023after the close | $67.20M | -15.4% | -$0.43 | -$0.18 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023after the close | $70.30M | -12.8% | -$0.46 | -$0.18 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 10, 2023after the close | $77.30M | -2.6% | -$0.44 | -$0.11 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 27, 2023after the close | $82.40M | +4.0% | -$0.34 | -$0.07 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022after the close | $79.40M | +5.0% | -$0.32 | -$0.06 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022after the close | $80.60M | – | -$0.41 | -$0.13 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022after the close | $79.40M | – | -$0.37 | -$0.13 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022after the close | $79.20M | – | -$0.31 | -$0.03 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 28, 2021after the close | $75.60M | – | -$0.23 | $0.07 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 29, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 5, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 24, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 7, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
CareDx's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| revenueGAAP | FY2026 | $520.00M – $530.00M | $420.00M – $444.00M | Raised | Oct 29, 2026 |
| revenue | FY2026 | $490.00M – $500.00M | – | New | Jul 30, 2026 |
| adjusted EBITDAnon-GAAP | FY2026 | $66.00M – $78.00M | – | New | Jul 30, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $90.00M – $100.00M | $30.00M – $45.00M | Raised | Oct 29, 2026 |
| revenue | FY2027 | $500.00M | $500.00M | Reaffirmed | Apr 30, 2025 |
| adjusted EBITDAnon-GAAP | FY2027 | $100.00M | – | New | Apr 30, 2025 |
| adjusted EBITDAnon-GAAP | FY2027 | 20% | – | New | Jan 13, 2025 |
Guidance vs results
The last range CareDx gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $372.00M – $376.00M | $379.50MΣ4Q | Above range |
Guidance history
Every forecast CareDx put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 29, 2026 | Adjusted EBITDA | FY2026 | $90.00M – $100.00M | Raised |
| Oct 29, 2026 | revenue | FY2026 | $520.00M – $530.00M | Raised |
| Jul 30, 2026 | adjusted EBITDA | FY2026 | $66.00M – $78.00M | New |
| Jul 30, 2026 | revenue | FY2026 | $490.00M – $500.00M | New |
| Feb 24, 2026 | adjusted EBITDA | FY2026 | $30.00M – $45.00M | New |
| Feb 24, 2026 | revenue | FY2026 | $420.00M – $444.00M | New |
| Nov 4, 2025 | adjusted EBITDA | FY2025 | $35.00M – $39.00M | New |
| Nov 4, 2025 | revenue | FY2025 | $372.00M – $376.00M | New |
| Aug 6, 2025 | adjusted EBITDA | FY2025 | $29.00M – $33.00M | Reaffirmed |
| Aug 6, 2025 | revenue | FY2025 | $367.00M – $373.00M | Narrowed |
| Apr 30, 2025 | adjusted EBITDA gain | FY2025 | $29.00M – $33.00M | Reaffirmed |
| Apr 30, 2025 | adjusted EBITDA | FY2027 | $100.00M | New |
| Apr 30, 2025 | revenue | FY2025 | $365.00M – $375.00M | Reaffirmed |
| Apr 30, 2025 | revenue | FY2027 | $500.00M | Reaffirmed |
| Feb 26, 2025 | adjusted EBITDA gain | FY2025 | $29.00M – $33.00M | New |
| Feb 26, 2025 | revenue | FY2025 | $365.00M – $375.00M | Reaffirmed |
| Jan 13, 2025 | adjusted EBITDA | FY2027 | 20% | New |
| Jan 13, 2025 | revenue | FY2025 | $370.00M | New |
| Jan 13, 2025 | revenue | FY2027 | $500.00M | New |
| Nov 4, 2024 | adjusted EBITDA gain | FY2024 | $18.00M – $22.00M | Raised |
| Nov 4, 2024 | non-GAAP gross margin | FY2024 | 69% | Raised |
| Nov 4, 2024 | revenue | FY2024 | $327.00M – $331.00M | Raised |
| Jul 31, 2024 | adjusted EBITDA gain | FY2024 | $9.00M – $15.00M | New |
| Jul 31, 2024 | non-GAAP gross margin | FY2024 | 67% – 68% | New |
| Jul 31, 2024 | revenue | FY2024 | $320.00M – $328.00M | Raised |
| May 9, 2024 | revenue | FY2024 | $274.00M – $282.00M | Raised |
| Feb 28, 2024 | revenue | FY2024 | $260.00M – $274.00M | New |
| Nov 8, 2023 | revenue | FY2023 | $274.00M – $278.00M | Raised |
| Aug 8, 2023 | revenue | FY2023 | $240.00M – $260.00M | Lowered |
| Feb 27, 2023 | revenue | FY2023 | $328.00M – $338.00M | New |
| Nov 3, 2022 | revenue expectations | FY2022 | $320.00M – $325.00M | Lowered |
| Aug 4, 2022 | revenue expectations | FY2022 | $325.00M – $335.00M | Lowered |
| May 5, 2022 | revenue expectations | FY2022 | $330.00M – $350.00M | Reaffirmed |
| Feb 24, 2022 | revenue | FY2022 | $330.00M – $350.00M | New |
| Oct 28, 2021 | revenue | FY2021 | $290.00M – $293.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases CareDx filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- News
- News
- Results
- Results
- Update
See a number that looks wrong?